<DOC>
	<DOCNO>NCT00835172</DOCNO>
	<brief_summary>The objective study compare relative bioavailability glimepiride 4 mg tablet ( manufacture TEVA Pharmaceutical Industries , Ltd. distribute TEVA Pharmaceuticals USA ) AMARYLÂ® tablet ( Aventis ) healthy , adult , non-smoking subject non-fasting condition .</brief_summary>
	<brief_title>Glimepiride 4 mg Tablets Under Non-Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>All subject select study nonsmoker least 18 year age . Subjects BMI ( body mass index ) 30 less . Each subject shall give general physical examination within 28 day initiation study . Such examination include , limited , blood pressure , general observation , history . Each female subject give serum pregnancy test part prestudy screen process . Adequate blood urine sample obtain within 28 day begin first period end trial clinical laboratory measurement . Clinical laboratory measurement include follow : Hematology : hemoglobin , hematocrit , red blood cell count , platelet , whit blood cell count ( differential ) . Clinical Chemistry : creatinine , BUN , glucose , SGOT/AST , SGPT/ALT , bilirubin , alkaline phosphatase . Urine Analysis : pH , specific gravity , protein , glucose , ketone , bilirubin , occult blood , cell . HIV Screen : prestudy . HepatitisB , C Screen : prestudy . Drugs Abuse Screen : prestudy checkin . Subjects select normal . Subjects significant recent history chronic alcohol consumption , drug addiction , serious gastrointestinal , renal , hepatic cardiovascular disease , tuberculosis , epilepsy , asthma , diabetes , psychosis glaucoma eligible study . Subjects whose clinical laboratory test value great 20 % outside normal range may retested . If clinical value outside range retesting , subject eligible participate study unless clinical investigator deem result significant . Subjects history allergic response class drug test exclude study . Subjects use tobacco form eligible participate study . Three month abstinence require . All subject urine sample assay presence drug abuse part clinical laboratory screening procedure dose period checkin . Subjects found urine concentration test drug allow participate . Subjects donate blood and/or plasma least thirty ( 30 ) day prior first dose study . Subjects take investigational drug within thirty ( 30 ) day prior first dose study allow participate . Female subject pregnant , breastfeeding , likely become pregnant study allow participate . Female subject childbearing potential must either abstain sexual intercourse use reliable barrier method ( e.g . condom , IUD ) contraception course study ( first dose last blood collection ) allow participate . Female subject use hormonal oral contraceptive within 14 day dose implanted injected hormonal contraceptive within 180 day dose allowed participate . All female subject screen pregnancy checkin study period . Subjects positive inconclusive result withdrawn study . Subjects tolerate venipuncture allow participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>